Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 4/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 9/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877861 | 0.90 | GLS (0.48) | CYP17A1GLSLCKAOC3DRD2 | |
| SCHEMBL3933137 | 0.90 | GLS (0.46) | CYP17A1GLSLCKAOC3DRD2 | |
| SCHEMBL27634079 | 0.89 | GLS (0.41) | CYP17A1GLSLCKAOC3HDAC1 | |
| SCHEMBL27633644 | 0.87 | GLS (0.42) | CYP17A1GLSLCKAOC3DRD2 | |
| SCHEMBL27626542 | 0.87 | GLS (0.47) | GLSLCKAOC3HDAC1HDAC6 | |
| SCHEMBL27626596 | 0.87 | AOC3 (0.49) | CYP17A1GLSLCKAOC3HDAC1 | |
| SCHEMBL3934593 | 0.86 | ALDH1A1 (0.50) | CYP17A1GLSLCKAOC3 | |
| SCHEMBL27654555 | 0.86 | GLS (0.39) | CYP17A1GLSLCKAOC3HDAC1 | |
| SCHEMBL4867181 | 0.85 | AOC3 (0.48) | AOC3 | |
| SCHEMBL27634161 | 0.85 | HDAC1 (0.39) | CYP17A1GLSLCKAOC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | CYP17A1 2790/4885GLS 3490/4885LCK 3431/4885 |
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | CYP17A1 3237/4885GLS 2685/4885LCK 3639/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | CYP17A1 3226/4885GLS 3054/4885LCK 3985/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | CYP17A1 3237/4885GLS 2685/4885LCK 3639/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | CYP17A1 3648/4885GLS 2577/4885LCK 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.